RCS - Physiomics PLC - PYC to present and exhibit at SITC Annual Meeting

PhysiomicsAnnouncement

09/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221109:nRSI7467Fa&default-theme=true

RNS Number : 7467F  Physiomics PLC  09 November 2022

9 November 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Conference presentation

 

Physiomics to present and exhibit at SITC Annual Meeting

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict
the effects of cancer treatment regimens for the biopharma industry, is
pleased to announce that it is participating in the 37(th) Annual Meeting of
the Society for Immunotherapy of Cancer ("SITC"), being held this week on 8-12
November 2022 in Boston, USA.

 

The Company will be presenting an original poster entitled: "Establishing the
preclinical PKPD relationship for NM32-2668 a ROR1 targeting T cell
engager".  Physiomics is co-authoring the poster with client Numab
Therapeutics ("Numab") whose investigational drug NM32 is currently in
IND-enabling studies.  NM32 is a tri-specific anti-ROR1/CD3/HSA antibody
based on Numab's scMATCH3 format which induces T cell-mediated lysis of
tumours expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).

 

The pharmacokinetic and pharcodynamic models developed during this work
provide quantitative confirmation of the mechanism of action of NM32-2668. The
model will support the establishment of a first-in-human starting dose and a
strategy to enable clinical effective dose selection.

 

The poster (Abstract #1293) will be presented on 10 November from 0900-1900
EST, with the presenting authors attending at lunch (1140-1310) and during the
poster reception (1930-2100).  The abstract is now available in Journal for
ImmunoTherapy of Cancer's November 2022 Issue Supplement, which can be
accessed at: https://jitc.bmj.com/content/10/Suppl_2/A1341
(https://jitc.bmj.com/content/10/Suppl_2/A1341) . A copy of the poster will be
posted on Physiomics' website at 0900 EST (1400 GMT) on the same day at:
https://www.physiomics.co.uk/resources
(https://www.physiomics.co.uk/resources) .

 

The Company will have substantial presence at the conference comprising both
scientific and business development team members and will also host a stand in
the main conference meeting hall (booth #236).  If you'd like to meet the
team at our booth please drop by or use this link to book a meeting:
https://www.physiomics.co.uk/sitc-2022/
(https://www.physiomics.co.uk/sitc-2022/) .

 

SITC is the world's leading member society of medical professionals dedicated
to advancing cancer immunotherapy and biological therapy through its
initiatives, educational sessions, and collaborative endeavours. More
information about the conference may be found using the following link:
https://www.sitcancer.org/2022/home (https://www.sitcancer.org/2022/home) .

 

Dr Jim Millen, CEO said: "It's great to be able to attend high profile
conferences such as SITC in person again, and a privilege to be presenting
important new work there.  The team and I look forward for our meetings with
existing clients attending SITC as well as potential new clients based in the
Boston area."

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFTLRLTIIF